Foundayo, Lilly's once-daily oral GLP-1 small molecule, hit roughly 17,000 US prescriptions for the week ending May 15, per the latest peptide-news digest ↗ summarizing a Citi client note. That is Lilly's first weekly print above 15,000 since the drug launched on April 6. Novo Nordisk's Wegovy ↗ pill, the once-daily oral semaglutide 25 mg formulation, recorded roughly 142,000 prescriptions in the same week. The ratio is 8.3 Wegovy-pill scripts for every Foundayo script. Three weeks ago the ratio was 20 to 1.
The six weeks
Foundayo's week-by-week trajectory since launch reads 1,390, then 3,707, then 5,612, then 7,335, then 10,248, then about 17,000. Each weekly print is bigger than the prior one, and the week-over-week growth rates have not slowed. Week 6 added 6,800 prescriptions over Week 5, the biggest single-week absolute increase of the launch. The Wegovy pill, by contrast, grew from roughly 113,000 weekly prescriptions in early May to roughly 142,000 by mid-May, an increase of 26 percent over the same interval that Foundayo grew 200 percent.
What changed in three weeks
The earlier Wegovy-pill-vs-Foundayo piece on May 4 ↗ framed the 20-to-1 ratio as a structural commercial gap that the section expected to widen rather than narrow. That framing has aged. The gap narrowed three weeks running, and the Foundayo trajectory is steepening rather than flattening.
Two things drove the compression. First, pharmacy-benefit-manager coverage activated at the largest US plans during early May, opening Foundayo to a population of patients whose plans had not previously paid for it. The Week 5 to Week 6 jump from 10,248 to 17,000 is the size of jump that PBM-activation events typically produce. Second, Lilly's late-May television advertising launch is still upcoming. The current curve reflects mostly the prescriber-channel ramp without consumer-pull pressure. The next two prints will show whether the TV launch adds another step or whether the curve flattens at the new level.
Wegovy pill's curve, by contrast, looks like it is on a more mature growth trajectory after a January launch that had four months of compounding before the early-May print. The pill's 113,000-to-142,000 weekly print interval is a 26 percent gain over the same three-week interval that Foundayo tripled. Either Foundayo is now at the steep part of an S-curve that Wegovy pill has already passed, or the Wegovy pill is approaching the natural ceiling of US patients who can be switched from compounded or injectable formulations onto the branded oral.
The Citi guidance
The bank kept its $146 million Foundayo Q2 revenue estimate and its $1.6 billion 2026 full-year estimate after the print. The 17,000 weekly print is consistent with both. Roughly half the year remains, and Foundayo would need to average around 75,000 weekly prescriptions across the second half of 2026 to hit the $1.6 billion full-year number at current realized pricing. That is a four-fold step from the current run rate, and the question the next six prints will answer is whether the trajectory's slope supports a four-fold expansion or only a two-fold one. Lilly's TV launch is the lever that the model assumes will close most of the gap.
What it doesn't change
Wegovy pill still has the structural lead. An 8.3-to-1 ratio is a narrower 8.3-to-1, not a closed race. Novo's parallel CHMP positive opinion on May 22 ↗ added a Q3 2026 EU launch for the Wegovy pill to its US trajectory. Lilly's Foundayo has no EU regulatory action pending and remains a US-only product for the time being. The compounded-GLP-1 closure that the FDA finalized in late April continues to favor the company with the larger installed prescriber base, and Novo's semaglutide ↗ franchise (Ozempic for type 2 diabetes, Wegovy injectable for obesity, Wegovy pill for obesity, Rybelsus for type 2 diabetes) covers more prescriber entry points than Lilly's single-indication Foundayo file.
Platform note
The GLP-1R ↗ target page anchors the metabolic corner of peptidemodel. Wegovy pill is the peptide drug on the comparison: semaglutide is a 31-amino-acid acylated analog of native GLP-1, formulated with the SNAC absorption enhancer to survive the stomach. Foundayo is orforglipron, a small molecule that binds the same receptor by a different chemistry and is the first oral GLP-1 that is not a peptide. The platform's design space stays peptide-focused, and the running observation that the peptide-vs-small-molecule split aligns cleanly with the Novo-vs-Lilly split of the US oral GLP-1 market remains accurate. What the latest print sharpens is that the small-molecule side is not stuck. It is climbing.